Advertisement

Ads Placeholder
Loading...

Nuvalent, Inc.

NUVLNASDAQ
Healthcare
Biotechnology
$105.43
$-0.21(-0.20%)
U.S. Market opens in 27h 56m

Nuvalent, Inc. (NUVL) Stock Overview

Explore Nuvalent, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap7.7B
P/E Ratio-18.62
EPS (TTM)$-5.85
ROE-0.42%
Fundamental Analysis

AI Price Forecasts

1 Month$106.48
3 Months$114.26
1 Year Target$116.77

NUVL Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Nuvalent, Inc. (NUVL) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 62.67, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $116.77.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -18.62 and a market capitalization of 7.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-0.20%
5-Day Change
7.58%
1-Month Change
5.20%
3-Month Change
4.55%
6-Month Change
25.18%
Year-to-Date (YTD) Change
4.55%
1-Year Change
54.32%
3-Year Change
291.21%
5-Year Change
462.29%
All-Time (Max) Change
462.29%

Contact Information

857 357 7000
One Broadway, Cambridge, MA, 02142

Company Facts

1,620 Employees
IPO DateJul 29, 2021
CountryUS
Actively Trading

Frequently Asked Questions